Vigabatrin for the Treatment of Cocaine Dependency
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent
subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use
of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher
than seen in subjects treated with placebo in addition to counseling.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Collaborators:
National Institute on Drug Abuse (NIDA) VA Office of Research and Development